ReviewJournal of the American Society of Nephrology : JASN2007
New approaches to the treatment of dense deposit disease.
Review in Journal of the American Society of Nephrology : JASN, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 229 citations in OpenAlex.
- Glycosaminoglycans and Their Role in Capillary Walls.Advances in experimental medicine and biology · 2026Review
- Article
- Clinical Profile and Outcome of C3-Dominant Glomerulonephritis: Retrospective Study.Kidney & blood pressure research · 2026Observational
- The Retinal Complications of C3 Dense Deposit Disease: A Scoping Review.Vision (Basel, Switzerland) · 2025Review
- Favorable outcome in children with dense deposit disease with the use of long-term mycophenolate mofetil and high-dose alternate-day steroids.Pediatric nephrology (Berlin, Germany) · 2025Article
- Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.Kidney international reports · 2025Article
- Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathy.Frontiers in immunology · 2025Article
- Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.Pediatric nephrology (Berlin, Germany) · 2024Article
- The Production of Complement Inhibitor Proteins in Mammalian Cell Lines-Light at the End of the Tunnel?Biomedicines · 2024Review
- Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- The role of complement in kidney disease.Nature reviews. Nephrology · 2023Review
- Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Kidney international reports · 2023Article
- Complement: Functions, location and implications.Immunology · 2023Review
- [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].Wiener klinische Wochenschrift · 2023Article
- Recurrent C3 Glomerulonephritis along with BK-Virus-Associated Nephropathy after Kidney Transplantation: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Complement: The Road Less Traveled.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.Frontiers in medicine · 2023Review
- C3 Glomerulopathy: A Review with Emphasis on Ultrastructural Features.Glomerular diseases · 2022Review
- Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children.Translational pediatrics · 2021Article
- Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice.Stem cell research & therapy · 2021Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 7 countries.
Funding
Abstract
The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.